• Participant or legal representative is able to provide written informed prior to performing any protocol-related procedures

• Is willing and able to comply with scheduled visits, treatment schedule, laboratory testing and other requirements of the study

• Men or women at least 18 years of age with histologically or cytologically confirmed non-small cell lung cancer

• Previous history of other than lung cancer is allowed if no active treatment for that cancer within 1 year

• Life expectancy of at least 6 months

• De novo stage IV or recurrent NSCLC without actionable mutation (e.g. EGFR/ ALK/ ROS-1) that was previously treated with either PD-1 / PD-L1 or the combination of PD1/PDL1 and cytotoxic chemotherapy, no more than 2 systemic regimens for metastatic disease with measurable disease \*. Maintenance therapy will be considered part of the 1 regimen

• At least 1 measurable lesion

• PDL1 TPS score less than 1% or unknown: first-line must be PD1/PDL1 inhibitor in combination with chemotherapy

• Early stage (I-III) NSCLC treated with adjuvant or neoadjuvant chemotherapy then PD1/PDL1 inhibitor treatment for recurrent disease

• Recurrent Unresectable stage III NSCLC treated with prior chemoradiation followed by maintenance PD1/PDL1 inhibitor with measurable disease

• Eastern Cooperative Group (ECOG) Performance Status 0 - 2

• Is able to swallow oral medications

• Adequate hematologic function

• Adequate organ function